

# Pamela M Pollock

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1638668/publications.pdf>

Version: 2024-02-01

62  
papers

12,174  
citations

117571

34  
h-index

128225

60  
g-index

66  
all docs

66  
docs citations

66  
times ranked

15433  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated genomic characterization of endometrial carcinoma. <i>Nature</i> , 2013, 497, 67-73.	13.7	4,075
2	Molecular classification of cutaneous malignant melanoma by gene expression profiling. <i>Nature</i> , 2000, 406, 536-540.	13.7	1,877
3	High frequency of BRAF mutations in nevi. <i>Nature Genetics</i> , 2003, 33, 19-20.	9.4	1,547
4	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3388-3397.	0.8	398
5	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. <i>Modern Pathology</i> , 2015, 28, 836-844.	2.9	343
6	Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells. <i>Cancer Research</i> , 2005, 65, 6282-6293.	0.4	300
7	Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. <i>Oncogene</i> , 2007, 26, 7158-7162.	2.6	284
8	Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. <i>Nature Genetics</i> , 2003, 34, 108-112.	9.4	260
9	Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 6146-6153.	3.2	213
10	Microarray expression profiling in melanoma reveals a BRAF mutation signature. <i>Oncogene</i> , 2004, 23, 4060-4067.	2.6	169
11	Compilation of somatic mutations of the CDKN2 gene in human cancers: Non-random distribution of base substitutions. , 1996, 15, 77-88.		155
12	FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features. <i>PLoS ONE</i> , 2012, 7, e30801.	1.1	150
13	A genome-based strategy uncovers frequent BRAF mutations in melanoma. <i>Cancer Cell</i> , 2002, 2, 5-7.	7.7	139
14	Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation. <i>Cancer Research</i> , 2008, 68, 6902-6907.	0.4	134
15	The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors. <i>Neoplasia</i> , 2013, 15, 975-IN30.	2.3	116
16	Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma. <i>Molecular Cancer Research</i> , 2009, 7, 41-54.	1.5	112
17	Targeting mutant fibroblast growth factor receptors in cancer. <i>Trends in Molecular Medicine</i> , 2011, 17, 283-292.	3.5	112
18	Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes. <i>Cancer Research</i> , 2009, 69, 5312-5320.	0.4	103

#	ARTICLE	IF	CITATIONS
19	Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i> -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <i>OncImmunity</i> , 2017, 6, e1264565.	2.1	102
20	p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 895-902.	1.9	90
21	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. <i>EBioMedicine</i> , 2015, 2, 671-680.	2.7	86
22	A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014, 135, 38-43.	0.6	82
23	miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. <i>Oncotarget</i> , 2015, 6, 17753-17763.	0.8	81
24	Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. <i>Oncogene</i> , 1997, 15, 2999-3005.	2.6	78
25	PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. <i>Melanoma Research</i> , 2002, 12, 565-575.	0.6	63
26	Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: Evidence for common founders and independent mutations. , 1998, 11, 424-431.		61
27	A crystallographic snapshot of tyrosine <i>trans</i> -phosphorylation in action. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 19660-19665.	3.3	61
28	p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 781-794.	1.5	59
29	Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. <i>Carcinogenesis</i> , 2006, 27, 1778-1786.	1.3	55
30	FGFR2 as a molecular target in endometrial cancer. <i>Future Oncology</i> , 2009, 5, 27-32.	1.1	55
31	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 1478-1492.	1.4	50
32	XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. <i>Anti-Cancer Drugs</i> , 2013, 24, 181-188.	0.7	46
33	FGFR2 mutations are rare across histologic subtypes of ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 117, 125-129.	0.6	45
34	Homodimerization Controls the Fibroblast Growth Factor 9 Subfamily's Receptor Binding and Heparan Sulfate-Dependent Diffusion in the Extracellular Matrix. <i>Molecular and Cellular Biology</i> , 2009, 29, 4663-4678.	1.1	44
35	CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. , 1997, 73, 531-536.		43
36	FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 366-373.	0.6	40

#	ARTICLE	IF	CITATIONS
37	Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-mb interval. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 56-64.	1.5	37
38	Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. <i>Molecular Cancer</i> , 2012, 11, 75.	7.9	36
39	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. <i>Modern Pathology</i> , 2018, 31, 1851-1861.	2.9	35
40	Mutations in exon 3 of the $\beta$ -catenin gene are rare in melanoma cell lines. <i>Melanoma Research</i> , 2002, 12, 183-186.	0.6	34
41	Lucky draw in the gene raffle. <i>Nature</i> , 2002, 417, 906-907.	13.7	34
42	PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 637-648.	1.9	34
43	Cellular Settings Mediating Src Substrate Switching between Focal Adhesion Kinase Tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) Tyrosine 734*. <i>Journal of Biological Chemistry</i> , 2011, 286, 42303-42315.	1.6	32
44	A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding. <i>American Journal of Human Genetics</i> , 2016, 98, 1159-1169.	2.6	32
45	Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A Trans PORTEC initiative. <i>Gynecologic Oncology</i> , 2017, 146, 327-333.	0.6	26
46	Fibroblast Growth Factor Receptor Inhibition Synergizes With Paclitaxel and Doxorubicin in Endometrial Cancer Cells. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1.	1.2	23
47	The $\beta$ -melanoma-enriched <sup>TM</sup> microRNA miR-4731-5p acts as a tumour suppressor. <i>Oncotarget</i> , 2016, 7, 49677-49687.	0.8	21
48	Mutation analysis of the CDKN2A promoter in Australian melanoma families. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 89-94.	1.5	20
49	Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents. <i>Cancer Discovery</i> , 2015, 5, 355-357.	7.7	16
50	Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer. <i>Genome Medicine</i> , 2022, 14, 3.	3.6	16
51	hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases. <i>DNA Repair</i> , 2017, 54, 30-39.	1.3	15
52	Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. <i>Theranostics</i> , 2020, 10, 2095-2114.	4.6	15
53	Endometrial cancer cells exhibit high expression of p110 $\beta$ and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. <i>Oncotarget</i> , 2017, 8, 3881-3894.	0.8	15
54	Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk. <i>Human Reproduction</i> , 2008, 23, 1661-1668.	0.4	14

#	ARTICLE	IF	CITATIONS
55	FGFR2b activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer. <i>Journal of Cell Science</i> , 2018, 131, .	1.2	14
56	Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2 mutant endometrial cancer. <i>Molecular Oncology</i> , 2019, 13, 738-756.	2.1	12
57	CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin. <i>International Journal of Cancer</i> , 2001, 93, 361-367.	2.3	10
58	Loss of Rearranged L-Myc Fusion (RLF) results in defects in heart development in the mouse. <i>Differentiation</i> , 2017, 94, 8-20.	1.0	10
59	FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes. <i>Clinical Cancer Research</i> , 2020, 26, 4569-4580.	3.2	10
60	Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer. <i>Cancers</i> , 2021, 13, 1703.	1.7	8
61	A homologue of the Drosophila Son of Sevenless gene maps to mouse chromosome 17. <i>Genomics</i> , 1993, 18, 733-734.	1.3	3
62	Lineage-Specific Biomarkers Predict Response to FGFR Inhibition. <i>Cancer Discovery</i> , 2012, 2, 1081-1083.	7.7	1